Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Efficacy of Relenza Against Influenza A and B

NCT01156701 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01156701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01156701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Efficacy of Relenza Against Influenza A and B
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
July 31, 2009
Completion date
May 31, 2010
Enrollment
171,705 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, bronchitis, bronchospasm, exacerbation of copd, influenza, human, otitis maedia, pneumonia, pulmonary disease, chronic obstructive, respiratory disease, sinusitis